PR Newswire·Nov 10, 2026, 8:15 AM ET

Atossa Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update

ATOS

Atossa Therapeutics reported third-quarter 2026 financial results & provided updates on corporate developments.
The company entered a Stapled Contingent Value Rights (CVR) Agreement on October 8, 2026, entitling holders to 25% of net proceeds up to $50 million from the sale of the first FDA priority review voucher awarded to Atossa.
No priority review voucher has been awarded yet, with no assurance that one will be received or monetized.
CFO Mark Daniel attended the Global Genes RARE Drug Development Symposium in Boston from September 9–11, 2026.
CEO Steven C. Quay attended the NORD Rare Diseases and Orphan Products Breakthrough Summit in Washington, D.C., from October 25–27, 2026.
The company anticipates FDA clearance of Investigational New Drug applications for (Z)-endoxifen in Duchenne Muscular Dystrophy & McCune-Albright Syndrome in early 2027.
Phase 2 clinical trials for (Z)-endoxifen in these rare disease indications are expected to initiate in 2027.
Karisma trial results will be presented at the San Antonio Breast Cancer Symposium in December 2026.
Select data from the Phase 2 I-SPY2 study evaluating (Z)-endoxifen combinations will also be presented at the December 2026 symposium.
Topline data from the Phase 2 EVANGELINE study is expected in the second quarter of 2027.
Total operating expenses were $5.9 million for the three months ended September 30, 2026, a decrease from $9.3 million in the same period in 2025.
Research & Development expenses decreased by 37% to $3.4 million for the quarter, primarily due to lower trial spend as enrollment was largely completed.
General & Administrative expenses decreased by 35% to $2.5 million for the quarter, driven by reduced headcount & legal fees following patent litigation resolution.
Interest income was $0.2 million for the quarter, down from $0.6 million in the prior year period, due to lower cash balances.
Cash & cash equivalents stood at $20.6 million as of September 30, 2026, compared to $41.3 million at the end of 2025.
Net loss for the three months ended September 30, 2026, was $5.6 million, or $0.56 per share.
Net loss for the nine months ended September 30, 2026, was $23.7 million, or $2.58 per share.
Atossa's lead candidate (Z)-endoxifen holds Orphan Drug Designation for DMD & Rare Pediatric Disease designation for DMD & MAS.

Company: Atossa Therapeutics Inc
Keywords: Atossa Therapeutics Inc